Cargando…

Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies

Since 2008, the direct-acting oral anticoagulants (DOACs) have expanded the therapeutic options of cardiovascular diseases with recognized clinical and epidemiological impact, such as non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE), and also in the preventive setting of orth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raschi, Emanuel, Bianchin, Matteo, Ageno, Walter, De Ponti, Roberto, De Ponti, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107188/ https://www.ncbi.nlm.nih.gov/pubmed/27696300 http://dx.doi.org/10.1007/s40264-016-0464-3

Ejemplares similares

Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
por: Bellesini, Marta, et al.
Publicado: (2020)

Drug-induced liver injury: Towards early prediction and risk stratification
por: Raschi, Emanuel, et al.
Publicado: (2017)

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors
por: Raschi, Emanuel, et al.
Publicado: (2019)

Direct-acting Oral Anticoagulants: An Overview
por: Salem, Hatem H.
Publicado: (2017)

Stroke, Migraine and Triptans: From Bedside to Bench
por: Raschi, Emanuel, et al.
Publicado: (2016)

Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study
por: Gatti, Milo, et al.
Publicado: (2019)

Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
por: Gatti, Milo, et al.
Publicado: (2021)

Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
por: Gatti, Milo, et al.
Publicado: (2020)

Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology
por: Dothel, Giovanni, et al.
Publicado: (2016)

Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
por: Gatti, Milo, et al.
Publicado: (2020)

Direct oral anticoagulants for unusual‐site venous thromboembolism
por: Riva, Nicoletta, et al.
Publicado: (2021)

Recurrence of pericarditis after influenza vaccination: a case report and review of the literature
por: Mei, Riccardo, et al.
Publicado: (2018)

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
por: Raschi, Emanuel, et al.
Publicado: (2020)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2021)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
por: Poluzzi, Elisabetta, et al.
Publicado: (2014)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
por: Raschi, Emanuel, et al.
Publicado: (2022)

Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres
por: Berardi, Lorenzo, et al.
Publicado: (2019)

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Poluzzi, Elisabetta, et al.
Publicado: (2015)

Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome
por: Giarretta, Igor, et al.
Publicado: (2022)

Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey
por: Girardi, Anna, et al.
Publicado: (2014)

Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
por: Girardi, Anna, et al.
Publicado: (2015)

Medications that interact with direct-acting oral anticoagulant exposure
por: de Vries, T. A. C., et al.
Publicado: (2021)

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2022)

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
por: Salvo, Francesco, et al.
Publicado: (2016)

Prescribers’ perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation
por: Generalova, Daria, et al.
Publicado: (2020)

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
por: Poluzzi, Elisabetta, et al.
Publicado: (2013)

Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database
por: Swart, Floor, et al.
Publicado: (2020)

Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
por: Kustos, Stephanie A., et al.
Publicado: (2019)

Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome
por: Sexton, Donal J., et al.
Publicado: (2018)

Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People
por: Lunghi, Carlotta, et al.
Publicado: (2022)

Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2023)

Direct oral anticoagulants for treatment of deep vein thrombosis: overview of systematic reviews
por: Brandão, Gustavo Muçouçah Sampaio, et al.
Publicado: (2018)

Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
por: De Ponti, Fabrizio
Publicado: (2013)

Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Raschi, Emanuel, et al.
Publicado: (2013)

Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1qdm645ung6onakli3101sa2aj